Stryker Corporation $SYK Shares Acquired by Swiss Life Asset Management Ltd

Swiss Life Asset Management Ltd raised its stake in shares of Stryker Corporation (NYSE:SYK) by 7.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 37,984 shares of the medical technology company’s stock after purchasing an additional 2,486 shares during the period. Swiss Life Asset Management Ltd’s holdings in Stryker were worth $14,042,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Norges Bank purchased a new stake in shares of Stryker during the 2nd quarter valued at $1,882,173,000. Alliancebernstein L.P. increased its holdings in shares of Stryker by 307.6% during the 2nd quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock worth $2,214,146,000 after buying an additional 4,223,366 shares during the last quarter. Corient Private Wealth LLC boosted its holdings in Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares during the last quarter. Strive Asset Management LLC purchased a new stake in Stryker during the third quarter valued at about $227,389,000. Finally, Credit Agricole S A purchased a new stake in Stryker during the third quarter valued at about $194,045,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $339.97 on Friday. The firm has a market capitalization of $130.10 billion, a PE ratio of 40.47, a price-to-earnings-growth ratio of 2.02 and a beta of 0.85. Stryker Corporation has a one year low of $328.23 and a one year high of $404.87. The stock’s 50 day moving average price is $363.89 and its 200 day moving average price is $366.43. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. During the same quarter last year, the firm posted $4.01 earnings per share. The business’s quarterly revenue was up 11.4% on a year-over-year basis. As a group, sell-side analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s payout ratio is 41.90%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 5.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SYK. Sanford C. Bernstein raised their price objective on Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Needham & Company LLC raised their price target on shares of Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a report on Friday, January 30th. Barclays reaffirmed an “overweight” rating and set a $469.00 price target on shares of Stryker in a research report on Monday, February 2nd. The Goldman Sachs Group set a $399.00 price objective on shares of Stryker in a research note on Friday, January 9th. Finally, Citizens Jmp raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 target price on the stock in a research note on Friday, December 19th. Fourteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $427.50.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.